December 23, 2009 โ The American College of Cardiologyโs (ACC) ACC.10 and i2 Summit 2010 is March 14-16, 2010, in Atlanta.
December 23, 2009 โ An investigational beta-blocker drug may be tested to see if it helps slow the progression of chronic heart failure in patients who have a specific genotype.
December 23, 2009 โ The Cleveland Clinic this week initiated a phase II trial examining a new oral therapy for the treatment of atherosclerosis in patients with stable coronary artery disease (CAD).
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
December 22, 2009 โ A new study is the first to specifically identify the year immediately around a womanโs final menstrual period as the time of most adverse changes in the lipid profile in women. The study appears in the Dec. 15-22, 2009, print double issue of the Journal of the American College of Cardiology (JACC) and the Prevention and Outcomes Quarterly Focus Issue.
December 22, 2009 โ A drug manufacturer recently filed paperwork with the FDA to produce a generic version of the cholesterol-lowering medication Vytorin.
December 21, 2009 โ Revised guidelines on the use of beta-blockers for noncardiac surgery say therapy should neither be initiated on the day of surgery, nor stopped abruptly peri- or postoperatively.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
December 21, 2009 โ The recently introduced GORE PROPATEN Vascular Graft has integrated rings that reduce the cross-sectional profile by 24 percent as compared to externally ringed grafts, and its radial reinforcement allows for improved blood flow.
December 18, 2009 โ Results from the Europella registry, evaluating the safety and feasibility of the Abiomed Impella 2.5 circulatory assist device in high-risk percutaneous coronary intervention (PCI) procedures, was published in the Dec. 15 issue of the Journal of the American College of Cardiology (JACC).
December 18, 2009 - The U.S. radiopharmacy network currently owned by Covidien is being sold to Triad Isotopes in a deal announced today. Covidien said it decided to divest its network of 37 Mallinckrodt radiopharmacies after evaluating the radiotracer market. The company said it wants to streamline its portfolio and concentrate resources in its faster-growing, higher-margin businesses.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
December 19, 2009 โ A new, non-electronic computed tomography (CT) radiation dosimeter was released this week. The RADView CT dosimeter is manufactured in the form of a badge, smaller than a credit card, and contains radiation-sensitive film.
December 17, 2009 โ The American College of Cardiology (ACC) recently certified LUMEDX, a provider of integrated cardiovascular imaging and information systems, as an ACC-NCDR ACTION Registry-GWTG software vendor.
December 17, 2009 โ The University of Virginia (UVa) in Charlottesville and AstraZeneca this week entered into a strategic research collaboration to enhance development of new treatments, primarily for coronary artery disease (CAD) with a secondary focus on peripheral vascular disease (PAD).
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
December 16, 2009 - Many healthcare providers who are pursuing meaningful use objectives and meeting with deadlines defined within the HITECH provision of the American Recovery and Reinvestment Act (ARRA) are challenged with securing the capital investment needed to meet the aggressive schedules.
December 16, 2009 - Non-enhanced CT for calcium detection is a reliable way to exclude obstructive coronary artery disease in patients with chest pain, according to a study published in the December issue of the American Journal of Cardiology.
December 16, 2009 โ The FDA's Endocrinologic and Metabolic Drugs Advisory Committee yesterday agreed AstraZeneca established sufficient benefit with trial data showing prophylactic benefit of prescribing CRESTOR (rosuvastatin calcium) to healthy individuals to prevent heart disease.